A Multicentre, Interventional, Non-randomized, Open-label, Single-group Phase III Study to Evaluate Plasma-Derived Antihaemophilic Factor/Von Willebrand Factor Concentrate (Biostate) for Immune Tolerance Induction in Male Paediatric Subjects With Haemophilia A (less than or equal to 2%) Who Have Developed High-titre Antibodies to Factor VIII (Factor VIII Inhibitors)

Trial Profile

A Multicentre, Interventional, Non-randomized, Open-label, Single-group Phase III Study to Evaluate Plasma-Derived Antihaemophilic Factor/Von Willebrand Factor Concentrate (Biostate) for Immune Tolerance Induction in Male Paediatric Subjects With Haemophilia A (less than or equal to 2%) Who Have Developed High-titre Antibodies to Factor VIII (Factor VIII Inhibitors)

Discontinued
Phase of Trial: Phase III

Latest Information Update: 11 Nov 2014

At a glance

  • Drugs Factor VIII/von Willebrand factor (Primary)
  • Indications Haemophilia A
  • Focus Therapeutic Use
  • Acronyms SWIFT-ITI
  • Sponsors CSL Behring
  • Most Recent Events

    • 10 Nov 2014 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top